Alexis JD - Hemogenyx Pharmaceuticals Independent Director

All Insiders . USA . 
Stock . Hemogenyx Pharmaceuticals Plc . Stakeholders . Insider . Alexis JD
HOPHF Stock  USD 1.24  0.00  0.00%   

Insider

Alexis JD is Independent Director of Hemogenyx Pharmaceuticals Plc
Phone44 79 0917 7311
Webhttps://www.hemogenyx.com

Hemogenyx Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1771) % which means that it has lost $0.1771 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3235) %, meaning that it generated substantial loss on money invested by shareholders. Hemogenyx Pharmaceuticals' management efficiency ratios could be used to measure how well Hemogenyx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Hemogenyx Pharmaceuticals Plc has accumulated 10.15 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hemogenyx Pharmaceuticals has a current ratio of 19.83, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hemogenyx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Hemogenyx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemogenyx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemogenyx to invest in growth at high rates of return. When we think about Hemogenyx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Deborah KnobelmanSenti Biosciences
50
Steven BellonFoghorn Therapeutics
60
Laurent ChardonnetPrelude Therapeutics
59
Nathanael GrayC4 Therapeutics
N/A
Eric LindquistCelcuity LLC
N/A
Abhinav ShuklaShattuck Labs
52
Mark MeierFennec Pharmaceuticals
N/A
Peggy ScherlePrelude Therapeutics
63
Anne McKayFennec Pharmaceuticals
70
Casi DeYoungShattuck Labs
54
Igor MDCelcuity LLC
N/A
Lauren WhiteC4 Therapeutics
N/A
Silvia BuonamiciMonte Rosa Therapeutics
N/A
Gavin MalenfantProMIS Neurosciences
61
James CollinsSenti Biosciences
59
Allan MDFoghorn Therapeutics
49
John CastleMonte Rosa Therapeutics
54
Filip MDMonte Rosa Therapeutics
51
Andrew MBAMonopar Therapeutics
53
Gerald MdFoghorn Therapeutics
N/A
Conor RichardsonShattuck Labs
N/A
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was founded in 2012 and is headquartered in London, the United Kingdom. Hemogenyx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people. Hemogenyx Pharmaceuticals Plc [HOPHF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-0.32
Return On Asset-0.18

Hemogenyx Pharmaceuticals Leadership Team

Elected by the shareholders, the Hemogenyx Pharmaceuticals' board of directors comprises two types of representatives: Hemogenyx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemogenyx. The board's role is to monitor Hemogenyx Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hemogenyx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemogenyx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Vladislav Sandler, CEO CoFounder
Alexis JD, Independent Director
Koen MD, Clinical Director
Andrew Wright, Financial Sec

Hemogenyx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hemogenyx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.32
Return On Asset-0.18
Current Valuation8.17 M
Shares Outstanding1.14 B
Shares Owned By Insiders13.01 %
Price To Book1.78 X
EBITDA(2.39 M)
Net Income(5.1 M)
Cash And Equivalents6.84 M
Cash Per Share0.01 X

Currently Active Assets on Macroaxis

BTCBitcoin
TRXTRON
BNBBinance Coin
ADACardano
XRPXRP

Other Information on Investing in Hemogenyx Pink Sheet

Hemogenyx Pharmaceuticals financial ratios help investors to determine whether Hemogenyx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemogenyx with respect to the benefits of owning Hemogenyx Pharmaceuticals security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY